Establishment Labs (NASDAQ:ESTA) Shares Gap Down – Time to Sell?

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $31.32, but opened at $30.53. Establishment Labs shares last traded at $31.83, with a volume of 62,015 shares changing hands.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ESTA shares. Needham & Company LLC began coverage on shares of Establishment Labs in a research report on Monday. They issued a “hold” rating on the stock. Stephens reissued an “overweight” rating and set a $52.00 target price on shares of Establishment Labs in a research report on Thursday, March 6th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $57.40.

Establishment Labs Price Performance

The company’s fifty day simple moving average is $36.45 and its 200-day simple moving average is $39.99. The stock has a market cap of $894.51 million, a P/E ratio of -12.02 and a beta of 0.77. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). The business had revenue of $44.51 million during the quarter, compared to the consensus estimate of $44.45 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. As a group, sell-side analysts forecast that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Hedge Funds Weigh In On Establishment Labs

Several hedge funds and other institutional investors have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Establishment Labs by 89.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,351 shares of the company’s stock valued at $1,789,000 after acquiring an additional 19,531 shares during the period. HighTower Advisors LLC grew its holdings in shares of Establishment Labs by 32.5% in the 3rd quarter. HighTower Advisors LLC now owns 10,311 shares of the company’s stock worth $446,000 after purchasing an additional 2,529 shares during the last quarter. Barclays PLC increased its position in shares of Establishment Labs by 9,643.3% during the 3rd quarter. Barclays PLC now owns 31,471 shares of the company’s stock worth $1,362,000 after purchasing an additional 31,148 shares in the last quarter. SkyView Investment Advisors LLC lifted its holdings in Establishment Labs by 30.5% during the 3rd quarter. SkyView Investment Advisors LLC now owns 12,000 shares of the company’s stock valued at $519,000 after purchasing an additional 2,805 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new position in Establishment Labs in the fourth quarter valued at about $12,898,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.